It is an epidermal growth factor inhibitor, that received a Notice of Compliance with conditions (NOC/c) on December 17, 2003 for third line therapy of locally advanced or metastatic non-small cell lung cancer (NSCLC).
Les conditions posées par l’avis de conformité concernent la fourniture à Santé Canada de preuves scientifiques tirées de vastes essais cliniques et montrant que : 1. L’Iressa® prolonge la survie; 2.